Showing results (231-240 of 384) with videos related to
Sort By:
Pageof 39
Cancers|February 11, 2023
Urinary PSA and Serum PSA for Aggressive Prostate Cancer DetectionNaseruddin Höti, Tung-Shing Lih, Mingming Dong, et al.BJU International|July 23, 2011
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-upEmmanuel S Antonarakis, Zhaoyong Feng, Bruce J Trock, et al.Urologic Oncology|June 14, 2011
Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomyPhillip M Pierorazio, Brian M Lin, Jeffrey K Mullins, et al.The Journal of Urology|November 17, 2016
The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific MortalityWon Sik Ham, Heather J Chalfin, Zhaoyong Feng, et al.The Journal of Urology|February 16, 2005
Serum leptin and pathological findings at the time of radical prostatectomyStephen J Freedland, Lori J Sokoll, Leslie A Mangold, et al.Cancer|October 30, 2003
A neurocomputational model for prostate carcinoma detectionPankaj Kalra, Joanna Togami, Gaurav Bansal B S, et al.The Journal of Urology|November 25, 2003
Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?Masood A Khan, H Ballentine Carter, Jonathan I Epstein, et al.Urology|April 21, 2007
EPCA-2: a highly specific serum marker for prostate cancerEddy S Leman, Grant W Cannon, Bruce J Trock, et al.BJU International|June 11, 2013
Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA densityMartin H Umbehr, Elizabeth A Platz, Sarah B Peskoe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance programAshley E Ross, Stacy Loeb, Patricia Landis, et al.Pageof 39